Stock Price Quote

ZIM LABORATORIES LTD.

NSE : ZIMLABBSE : 541400ISIN CODE : INE518E01015Industry : Pharmaceuticals & DrugsHouse : MNC
BSE103.39-0.43 (-0.41 %)
PREV CLOSE ( ) 103.82
OPEN PRICE ( ) 103.50
BID PRICE (QTY) 103.74 (1)
OFFER PRICE (QTY) 103.98 (1)
VOLUME 424
TODAY'S LOW / HIGH ( )103.39 104.63
52 WK LOW / HIGH ( )79.5 128.45
NSE103.57-0.22 (-0.21 %)
PREV CLOSE( ) 103.79
OPEN PRICE ( ) 103.36
BID PRICE (QTY) 103.56 (20)
OFFER PRICE (QTY) 103.81 (1)
VOLUME 10450
TODAY'S LOW / HIGH( ) 103.25 104.56
52 WK LOW / HIGH ( )79.49 128.9
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 1984
Management Info
Anwar Siraj Daud - Chairman Anwar Siraj Daud - Managing Director
Registered Office

Address Sadoday Gyan (Ground Floor), Opp. Nadt,Nelson Square, ,
Nagpur,
Maharashtra-440013

Phone 0712-2981960

Email info@zimlab.in

Website www.zimlab.in

Registrars Details
MUFG Intime India Pvt Ltd.
C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai
Listing : BSE, NSE

NEWS

28Apr Zim Laboratories informs about outcome
In compliance with Regulation 30 of the SEBI (Listing Obligations and Di..
09Apr ZIM Laboratories inks pact with Global
ZIM Laboratories has entered into a dossier license, product supply, and..
20Mar ZIM Laboratories’ arm gets marketing a
ZIM Laboratories’ wholly owned European subsidiary -- SIA ZIM Laboratori..
20Mar ZIM Laboratories rises as its arm gets
Zim Laboratories is currently trading at Rs. 85.92, up by 1.15 points or..
27Dec Zim Laboratories informs about closure
Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclo..

Financials

in Millions
QTR Mar 25 ANNUAL 25
Net Profit54.2000000000001117.45
Gross Profit 86.4800000000001 176.13
Operating Profit 167.91488.9
Net Sales 1085.153756.36

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Abbott India (BSE)
peergroup  31615.05 (0.22%)
M.Cap ( in Cr)67031.24
Kwality Pharma (BSE)
peergroup  1082.80 (5.25%)
M.Cap ( in Cr)1067.45
Gland Pharma (BSE)
peergroup  1734.00 (2.65%)
M.Cap ( in Cr)27832.30
Cipla (BSE)
peergroup  1537.95 (2.16%)
M.Cap ( in Cr)121592.34
Jubilant Pharmova (BSE)
peergroup  1125.90 (2.90%)
M.Cap ( in Cr)17427.75

Shareholding Pattern

NON-INSTITUTION 66.57%
PROMOTERS 33.26%
MUTUAL FUNDS/UTI 0%
FI/BANKS/INSURANCE 0%
GOVERNMENT 0%
FII 0%

About Zim Laboratories Ltd.

Zim Laboratories Ltd. was incorporated in the year 1984. Its today's share price is 103.39. Its current market capitalisation stands at Rs 505.87 Cr. In the latest quarter, company has reported Gross Sales of Rs. 3756.36 Cr and Total Income of Rs.3812.56 Cr. The company's management includes Ashok Bhatia, Kamlesh Shende, Padmakar Shrinivas Joshi, Kavita Loya, Prakash Pralhadrao Sapkal, Niraj Pukhraj Dhadiwal, Zulfiquar Murtaza Kamal, Anwar Siraj Daud, Anwar Siraj Daud, Piyush Siddeshwar Nikhade.

It is listed on the BSE with a BSE Code of 541400 , NSE with an NSE Symbol of ZIMLAB and ISIN of INE518E01015. It's Registered office is at Sadoday Gyan (Ground Floor), Opp. Nadt,Nelson Square, Nagpur-440013, Maharashtra. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are Paliwal Modani & Co, Raman S Shah & Co, SR Batliboi & Co LLP, Walker Chandiok & Co LLP

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.